BIMZELX

BIMZELX is a humanized interleukin-17A and F antagonist indicated for the treatment of:

• Moderate to severe
  
  
  plaque psoriasis (PSO)
  in adults who are candidates for systemic therapy or phototherapy. (
  
  
  1.1 Plaque Psoriasis

  BIMZELX is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
  )
  
• Adults with active
  
  
  psoriatic arthritis (PsA)
  . (
  
  
  1.2 Psoriatic Arthritis

  BIMZELX is indicated for the treatment of adults with active psoriatic arthritis.
  )
  
• Adults with active
  
  
  non-radiographic axial spondyloarthritis
  (
  
  
  nr-axSpA
  ) with objective signs of inflammation. (
  
  
  1.3 Non-Radiographic Axial Spondyloarthritis

  BIMZELX is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation.
  )
  
• Adults with active
  
  
  ankylosing spondylitis
  (
  
  
  AS
  ). (
  
  
  1.4 Ankylosing Spondylitis

  BIMZELX is indicated for the treatment of adults with active ankylosing spondylitis.
  )
  
• Adults with moderate to severe
  
  
  hidradenitis suppurativa (HS)
  . (
  
  
  1.5 Hidradenitis Suppurativa

  BIMZELX is indicated for the treatment of adults with moderate to severe hidradenitis suppurativa.
  )